KBC Group
TGTX icon

KBC Group’s TG Therapeutics TGTX Stock Holding History

KBC Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$293K Hold
5,335
– – ﹤0.01% 921
2026
Q1 		$177K Buy
5,335
+1,195
+29% +$35.6K ﹤0.01% 1022
2025
Q4 		$123K Hold
4,140
– – ﹤0.01% 1155
2025
Q3 		$150K Hold
4,140
– – ﹤0.01% 1034
2025
Q2 		$149K Sell
4,140
-2,887
-41% -$107K ﹤0.01% 989
2025
Q1 		$277K Buy
7,027
+67
+1% +$2.25K ﹤0.01% 904
2024
Q4 		$209K Buy
6,960
+2,285
+49% +$65.6K ﹤0.01% 1103
2024
Q3 		$109K Buy
4,675
+1,092
+30% +$23.8K ﹤0.01% 1236
2024
Q2 		$64K Buy
3,583
+437
+14% +$6.97K ﹤0.01% 1468
2024
Q1 		$48K Hold
3,146
– – ﹤0.01% 1586
2023
Q4 		$54K Hold
3,146
– – ﹤0.01% 1475
2023
Q3 		$26K Buy
+3,146
New +$43.9K ﹤0.01% 1844

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

KBC Group's TGTX Position: Q2 2026 in Review

KBC Group held its TG Therapeutics (TGTX) position steady in Q2 2026 at 5,335 shares worth $293K. The position accounts for ﹤0.01% of the portfolio, ranked #921.

KBC Group first reported a position in TGTX in Q3 2023 and has held it in 12 quarters since. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • KBC Group held 5,335 shares of TG Therapeutics worth $293K as of Q2 2026.
  • KBC Group left its TG Therapeutics share count unchanged in Q2 2026.
  • TG Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #921 holding.
  • KBC Group first reported a position in TG Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.